Today, Insmed Incorporated announced that Al Altomari has been elected to its Board of Directors, effective immediately. Including Mr. Altomari, Insmed’s Board of Directors now consists of seven members.
Donald j. Hayden, Insmed’s Executive Chairman, remarked, “Al brings to our Board nearly 30 years of valuable experience in the pharmaceutical industry, including more than 20 years focused on the development and marketing of specialty pharmaceutical products. We believe his expertise in these areas will be instrumental as we continue to execute on our development plan for ARIKACE®.”
Mr. Altomari added, “With top-line data for ARIKACE in the Company’s lead orphan indications, cystic fibrosis-related Pseudomonas lung infections, and non-TB Mycobacteria lung infections expected in 2013, this is an exciting time to be joining Insmed’s Board. I look forward to lending my specialty pharmaceutical development and marketing expertise to the Company’s Board and management team.”
Since October 2010, Mr. Altomari has served as President and Chief Executive Officer and board member at Agile Therapeutics, a privately held pharmaceutical company. Prior to being named President and CEO, he served as Agile’s Executive Chairman, during which time he closed a $45 million investment round in May 2010.
Prior to Agile, Mr. Altomari spent five years in multiple senior management positions at Barrier Therapeutics. He was directly responsible for placing the company’s commercial infrastructure and all sales and marketing functions for Barrier’s product portfolio; he also oversaw management of all worldwide business development initiatives. In 2008, as its CEO and member of the company’s Board of Directors, Mr. Altomari successfully completed the sale of the company to GlaxoSmithKline/Stiefel Laboratories.
From 1982-2003, Mr. Altomari held numerous executive roles in general management, commercial operations, business development, product launch preparation, and finance with Johnson & Johnson, where he successfully led the integration of Ortho Dermatological and Neutrogena Professional. Mr. Altomari also served as Vice President/Franchise Head of Ortho-McNeil Pharmaceutical’s Women’s Health Care Franchise, where he introduced several life cycle and new product development initiatives, including the launch of the contraceptive patch, ORTHO Evra™.
In July 2007, PharmaVoice Magazine recognized Mr. Altomari as one of its Top 100 Most Inspirational and Influential leaders in the Life Sciences Industry. He holds a Masters in Business Administration from Rider University and a Bachelor of Science from Drexel University. Mr. Altomari also serves on the advisory board for Le Bow College, Drexel University’s business school.
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html